Enovis (NYSE:ENOV) Trading Up 7.3% – Here’s What Happened

Shares of Enovis Corporation (NYSE:ENOV) were up 7.3% during trading on Thursday . The company traded as high as $21.16 and last traded at $21.5060. 111,748 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 1,073,055 shares. The stock had previously closed at $20.04.

Analysts Set New Price Targets

ENOV has been the topic of a number of research reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Enovis in a research report on Friday, April 10th. William Blair initiated coverage on Enovis in a report on Friday, April 17th. They issued an “outperform” rating for the company. Wells Fargo & Company dropped their price objective on Enovis from $42.00 to $40.00 and set an “overweight” rating on the stock in a research note on Friday, May 8th. Wall Street Zen downgraded Enovis from a “buy” rating to a “hold” rating in a report on Sunday, June 28th. Finally, Zacks Research lowered Enovis from a “hold” rating to a “strong sell” rating in a research report on Tuesday. Seven investment analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $44.50.

Enovis Trading Up 0.4%

The company has a debt-to-equity ratio of 0.87, a quick ratio of 1.05 and a current ratio of 2.04. The company’s fifty day simple moving average is $23.23 and its 200-day simple moving average is $23.86. The company has a market capitalization of $1.30 billion, a P/E ratio of -1.14 and a beta of 1.39.

Enovis (NYSE:ENOV) last posted its earnings results on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The business had revenue of $589.15 million for the quarter, compared to the consensus estimate of $572.02 million. During the same quarter last year, the firm posted $0.81 EPS. The company’s revenue for the quarter was up 5.4% on a year-over-year basis. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Research analysts predict that Enovis Corporation will post 3.12 earnings per share for the current year.

Insider Buying and Selling

In other Enovis news, insider Oliver Engert acquired 1,200 shares of Enovis stock in a transaction that occurred on Thursday, June 11th. The stock was bought at an average price of $21.62 per share, with a total value of $25,944.00. Following the completion of the purchase, the insider directly owned 51,840 shares of the company’s stock, valued at approximately $1,120,780.80. This represents a 2.37% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders have purchased a total of 4,200 shares of company stock valued at $92,084 over the last ninety days. Insiders own 2.90% of the company’s stock.

Institutional Trading of Enovis

Hedge funds and other institutional investors have recently bought and sold shares of the stock. AQR Capital Management LLC increased its holdings in shares of Enovis by 12.5% in the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after acquiring an additional 7,072 shares during the period. Goldman Sachs Group Inc. lifted its stake in shares of Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after purchasing an additional 73,116 shares during the last quarter. Empowered Funds LLC lifted its stake in shares of Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after purchasing an additional 749 shares during the last quarter. EverSource Wealth Advisors LLC boosted its position in Enovis by 125.4% during the second quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock valued at $40,000 after purchasing an additional 707 shares in the last quarter. Finally, Amundi boosted its position in Enovis by 24,405.0% during the second quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after purchasing an additional 9,762 shares in the last quarter. Institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.